程序性死亡受体1/程序性死亡配体1在甲状腺未分化癌的研究进展  

Research progress of programmed cell death-1/programmed cell death ligand-1 in anaplastic thyroid cancer

作　　者：杜衍 张生来[1] 张文杰[1] Du Yan;Zhang Shenglai;Zhang Wenjie(Department of General Surgery, Xinhua Hospital of Shanghai Jiaotong University of Medicine, Shanghai 200092, China)

机构地区：[1]上海交通大学医学院附属新华医院普外科,200092

出　　处：《中华实验外科杂志》2019年第4期783-785,共3页Chinese Journal of Experimental Surgery

摘　　要：甲状腺未分化癌是一种罕见、极具侵袭性的疾病,预后往往不良,总体生存时间仅以月计。有近半数患者诊断时已经处于局部晚期、或伴有远处转移,缺乏有效的治疗方式。目前,程序性死亡受体1(PD-1)/程序性死亡配体1(PD-L1)作为极具发展潜力的免疫治疗方式,已在多种肿瘤中显示出良好疗效。本文旨在对PD-1/PD-L1生物学作用、药物进展及在甲状腺未分化癌中的研究现状进行综述,有助于为甲状腺未分化癌的治疗提供一些新的思路。Anaplastic thyroid cancer is a rare and aggressive disease with a dismal prognosis and an overall survival measured in months.Nearly 50% of patients at diagnosis have locally advanced or distant metastases.Therefore, there is a lack of effective treatment.Recently, programmed cell death-1 (PD-1)/programmed cell death ligand-1(PD-L1), as a highly promising immune therapy, has shown good efficacy in a variety of tumors.This article aims to review biological effects, drug progression and research status of PD-1/PD-L1 in anaplastic thyroid cancer.It helps to provide some new ideas for the treatment of anaplastic thyroid cancer.

关 键 词：甲状腺未分化癌 免疫疗法 程序性死亡受体1/程序性死亡配体1 

分 类 号：R736.1[医药卫生—肿瘤]